登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要提示内容： 1、本次行权股票数量：2025年第四季度，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"） 2022年股票期权激励计划（以下简称"本次激励计划"）激励对象行权且完成股份过户登记的股票数量合 计为963.8570万股。 2、本次行权股票上市流通时间：本次激励计划采用自主行权方式行权，激励对象（除公司董事、高级 管理人员外）行权所得股票于行权日（T日）后的第二个交易日（T+2）日可上市交易。 2025年第四季度，公司本次激励计划激励对象行权且完成股份过户登记的股票数量合计为963.8570万 股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会第十三次（临时）会议 分别审议通过了《关于〈浙江康恩贝制药股份有限公司2022年股票期权激励计划（草案）〉及摘要的议 案》及其他相关议案，公司独立董事、监事会、律师均发表了相关 ...

Core Viewpoint - The announcement details the stock option incentive plan of Zhejiang Kangnbei Pharmaceutical Co., Ltd. for the third quarter of 2025, highlighting the number of shares exercised and the related procedures [1][2]. Summary by Sections Stock Option Exercise Details - In the third quarter of 2025, a total of 3.604973 million shares were exercised under the 2022 stock option incentive plan [2]. - The exercised shares will be tradable on the second trading day after the exercise date [2]. Decision-Making Process and Information Disclosure - The plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange and other designated media [2][3]. - The plan included the granting of 70 million stock options to eligible participants, with the first grant completed in November 2022 [3]. Adjustments to Stock Option Terms - The exercise price of the stock options was adjusted from 4.13 CNY to 3.98 CNY in June 2023, and further adjustments were made in July 2024 and June 2025 [3][4][5]. - The number of stock options granted was also adjusted, with 752.5 thousand reserved options granted in October 2023 [3][4]. Shareholder and Management Participation - A total of 97 participants exercised their options in the third quarter of 2025 [7]. - The shares resulting from the exercise are subject to a six-month lock-up period for directors and senior management [10]. Financial Impact and Fund Utilization - The exercise of options raised approximately 13.086052 million CNY, contributing to a total of 69.266768 million CNY raised to date, which will be used to supplement the company's working capital [12]. - The impact of the exercised shares on the company's financial status and operational results is not considered significant [12].

Core Points - The company announced the results of the stock option incentive plan for the second quarter of 2025, with a total of 492,437 shares exercised [1][8] - The stock option plan was initially approved in September 2022, allowing for the grant of 70 million stock options [1][2] - The exercise price of the stock options was adjusted multiple times, with the latest adjustment setting it at 3.78 yuan per share for the initial grant and 5.07 yuan for reserved options [3][4][5] Summary by Sections Incentive Plan Overview - The stock option incentive plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange [1][2] - The plan allows for the grant of stock options to 537 individuals, with a total of 62.475 million options registered [1][2] Adjustments to Exercise Price - The exercise price was adjusted from 4.13 yuan to 3.98 yuan in June 2023 following a cash dividend distribution [2][3] - Further adjustments were made in July 2024, reducing the exercise price to 3.78 yuan for initial options and 5.07 yuan for reserved options [4][5] Exercise Results - As of the second quarter of 2025, a total of 1,486,712.7 shares were exercised, with the total number of shares exercised reaching 49,243.7 shares [6][7] - The shares obtained through the exercise will be tradable two trading days after the exercise date [7] Impact on Share Capital Structure - The total number of shares increased from 2,584,412,009 to 2,584,904,446 after the exercise, with the distribution of shares remaining compliant with listing requirements [7][8] - The company raised 1.844387 million yuan from the exercise of stock options [7]